Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Parnate (tranylcypromine sulfate) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – May 2010 and November 2009

 

May 2010 Summary View

 

CONTRAINDICATIONS

In combination with sympathomimetics
  • Parnate should not be administered in combination with sympathomimetics, including amphetamines which may be found in many herbal preparations
  • Cerebral hemorrhage may also occur

 

 

November 2009 Summary View

 

CONTRAINDICATIONS

  • Parnate is contraindicated: In combination with selective norepinephrine reuptake inhibitors (SNRIs)

 

-
-